Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck (MRK) recently announced a dividend of $0.81 per share for Q4 2025 and gained Health Canada approval for KEYTRUDA® in treating cervical cancer. These developments align with Merck’s ongoing ...

Merck (MRK) announced on Monday that the Canadian regulator, Health Canada, has granted approval for its cancer drug Keytruda in combination with chemoradiotherapy (CRT) for the treatment of ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and ...

Merck's Q3 2023 earnings results will be announced on October 26th. In this preview, I highlight some issues to consider and news to look out for. Keytruda, Merck's immuno-oncology drug, continues ...

Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again. That prowess makes Keytruda’s recent string of failures more noteworthy.

Merck & Co on Thursday said it was in the market for deals of up to around $15 billion as it plans for a loss of revenue from its aging cancer immunotherapy Keytruda, the world's top-selling ...

Merck’s immuno-oncology blockbuster Keytruda was mentioned more than a dozen times in the company’s third-quarter earnings announcement, and not just because sales of the drug soared 62% to $3 ...

Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and ...